B cell receptor signaling related to resistance to <i>Helicobacter pylori</i> eradication therapy in gastric diffuse large B cell lymphoma

Torisu, Takehiro; Kawano, S; Miyawaki, Kohta; Yamamoto, Hidetaka; Ihara, Yutaro; Matsuno, Yuichi; Torisu, Kumiko; Sugio, Takeshi; Sasaki, Kenji; Shimakawa, Takashi; Katô, Kôji; Akashi, Koichi; Nakamura, Shotaro; Kitazono, Takanari

doi:10.1002/hon.2816

Cited by 4 publications

(3 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has been reported that in gastric DLBCL, the expression of BCL10, nuclear factor kappaB (p65), cytotoxin-associated gene A (CagA)[ 13 ] and CagA-signaling molecules is clinically and biologically H. pylori -dependent[ 5 ], or miR-200 was associated with the susceptible group for H. pylori [ 14 ]. Although knowledge about B-cell receptor signaling related to susceptibility to H. pylori eradication treatment in gastric DLBCL is advancing[ 15 ], clinical application is still difficult. In this study, molecular medical markers were not scrutinized, which was a limitation of our research.…”

Section: Discussionmentioning

confidence: 99%

Helicobacter pylori eradication treatment for primary gastric diffuse large B-cell lymphoma: A single-center analysis

Saito,

Mori,

Kajikawa

et al. 2023

World J Clin Cases

View full text Add to dashboard Cite

In recent years, metabolomics research has become a hot spot in the screening and treatment of cancer. It is a popular technique for the quantitative characterization of small molecular compounds in biological cells, tissues, organs or organisms. Further study of the tumor revealed that amino acid changes may occur early in the tumor. The rapid growth and metabolism required for survival result in tumors exhibiting an increased demand for amino acids. An abundant supply of amino acids is important for cancer to maintain its proliferative driving force. Changes in amino acid metabolism can be used to screen malignant tumors and improve therapeutic outcomes. Therefore, it is particularly important to study the characteristics of amino acid metabolism in colorectal cancer. This article reviews several specific amino acid metabolism characteristics in colorectal cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Helicobacter pylori eradication treatment for primary gastric diffuse large B-cell lymphoma: A single-center analysis

Saito,

Mori,

Kajikawa

et al. 2023

World J Clin Cases

View full text Add to dashboard Cite

show abstract

“…The most common mutation is EZH2, which confers a worse prognosis in the mostly germinal-center Type DLBCL [99]. Other reports confirmed that once BCR signaling is affected, H. plyori eradication alone cannot cure the disease [56]. The association of gastric MALT/DLBCL is high with H. pylori; as much as 75% of cases are positive compared to de novo gastric DLBCL, where only 36% positivity was found [27].…”

Section: Helicobacter Pylorimentioning

confidence: 99%

The Possible Role of Pathogens and Chronic Immune Stimulation in the Development of Diffuse Large B-Cell Lymphoma

Gergely,

Udvardy,

Illes

2024

Biomedicines

View full text Add to dashboard Cite

Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma. The disease is very heterogeneous, with distinct genetic alterations in subtypes. The WHO 2022 5th edition classification identifies several minor groups of large B-cell lymphoma where the pathogenetic role of viruses (like EBV and HHV-8) is identified. Still, most cases fall into the group of DLBCL not otherwise specified (NOS). No review focuses only on this specific lymphoma type in the literature. The pathogenesis of this entity is still not fully understood, but several viruses and bacteria may have a role in the development of the disease. The authors review critical pathogenetic events in the development of DLBCL (NOS) and summarize the data available on several pathogenetic viruses and bacteria that have a proven or may have a potential role in the development of this lymphoma type. The possible role of B-cell receptor signaling in the microenvironment is also discussed. The causative role of the Epstein–Barr virus (EBV), human herpesvirus-8 (HHV-8), Hepatitis C virus (HCV), human immunodeficiency virus (HIV), Hepatitis B virus (HBV), and other viruses are explored. Bacterial infections, such as Helicobacter pylori, Campylobacter jejuni, Chlamydia psittaci, Borrelia burgdorferi, and other bacteria, are also reviewed.

show abstract

“…A total of 179 citations were found on PubMed. Following title and abstracts review, seven (three retrospective, three prospective, and one combined) studies [10][11][12][13][14][15][16] met inclusions criteria, including three studies performed in Japan, two studies in Taiwan, and one each in Italy and in Germany. The others studies were ultimately excluded for different reasons (Figure 1).…”

Section: Descriptive Analysismentioning

confidence: 99%

Efficacy of Helicobater pylori eradication in patients with diffuse large B‐cell lymphoma of the stomach: A systematic review

Francesco

Manta

Marmo³

et al. 2022

European J of Haematology

View full text Add to dashboard Cite

Objectives The role of Helicobater pylori eradication in the treatment of high‐grade diffuse large B‐cell lymphoma (DLBCL) of the stomach is unclear. Methods We performed a systematic review and meta‐analysis of currently available data. DLBCL‐remission rate after eradication therapy, post‐remission maintenance, and response rate in the case of additional oncological therapy were extracted. Results By considering data of seven studies, the DLBCL remission was achieved in 81 (53.3%; 95% CI = 45.3–61.2) out of 152 H. pylori eradicated patients. The regression rate did not differ between pure DLCBL and DLCBL with MALT component, between stage I and stage II disease, and between Caucasians and Asians. Disease regression was maintained in all patients after at a median of 63 months (range: 46–29) follow‐up. In those non‐responders, DLBLC remission after additional chemo‐immunotherapy was achieved in 63 (98.4%; 95% CI = 95.4–100) out of 64 patients. Conclusions Data this systematic review suggest considering H. pylori eradication as first‐line therapy to treat infected patients with early‐stage, high‐grade gastric lymphoma.

show abstract

B cell receptor signaling related to resistance to Helicobacter pylori eradication therapy in gastric diffuse large B cell lymphoma

Cited by 4 publications

References 9 publications

Helicobacter pylori eradication treatment for primary gastric diffuse large B-cell lymphoma: A single-center analysis

Helicobacter pylori eradication treatment for primary gastric diffuse large B-cell lymphoma: A single-center analysis

The Possible Role of Pathogens and Chronic Immune Stimulation in the Development of Diffuse Large B-Cell Lymphoma

Efficacy of Helicobater pylori eradication in patients with diffuse large B‐cell lymphoma of the stomach: A systematic review

Contact Info

Product

Resources

About